Home' Australian Pharmacist : Australian Pharmacist September 2012 Contents Australian Pharmacist September 2012 I © Pharmaceutical Society of Australia Ltd.
1. The 12-month prevalence of PTSD in
Australia is estimated to be:
2. Which ONE of the following
statements regarding ASD and PTSD
is NOT correct?
a) ASD is diagnosed within two days
to one month following exposure to
b) A diagnosis of PTSD requires that
symptoms be experienced for at least
c) The majority of people recover from
trauma without developing ASD or
d) The only difference between ASD and
PTSD is the time within which they
occur following trauma.
3. Approximately what proportion
of cases of PTSD present with co-
morbid mental health conditions?
4. Australian guidelines recommend
which of the following options as
first-line therapy for PTSD?
c) Trauma-focused psychological
d) Atypical antipsychotics.
5. In the management of PTSD, which
class of medication has the best
evidence of effectiveness?
d) Atypical antipsychotics.
1. Creamer M, Burgess P, McFarlane AC. Post-traumatic stress
disorder: findings from the Australian National Survey of
Mental Health and Well-being. Psychol Med 2001;31:1237–
47. At: http://digital.library.adelaide.edu.au/dspace/
2. Reed RV, Fazel M, Goldring L. Post-traumatic stress disorder.
3. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress
disorder in the National Comorbidity Survey. Arch Gen
Psychiatry 1995;52:1048–60 .
4. Gradus JL, Qin P, Lincoln AK, et al. Posttraumatic stress disorder
and completed suicide. Am J Epidemiol 2010;171:721–7 . At:
5. Australian Centre for Posttraumatic Mental Health. Australian
guidelines for the treatment of adults with acute stress
disorder and posttraumatic stress disorder. 2007. At: www.
6. Forbes D, Creamer MC, Phelps AJ, et al. Treating adults with
acute stress disorder and post-traumatic stress disorder in
general practice: a clinical update. Med J Aust 2007;187:120–3 .
7. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders (DSM-IV ). 4th edn. Washington,
DC.: American Psychiatric Association; 2000.
8. Ehlers A, Gene-Cos N, Perrin S. Low recognition of post-
traumatic stress disorder in primary care. Lond J Primary Care
2009:36–42. At: www.londonjournalofprimarycare.org.uk/
9. Zimmerman M, Mattia JI. Is posttraumatic stress disorder
underdiagnosed in routine clinical settings? J Nerv Ment Dis
10. Breslau N, Peterson EL, Kessler RC, et al. Short screening scale
for DSM-IV posttraumatic stress disorder. Am J Psychiatry
11. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post
traumatic stress disorder (PTSD). Cochrane Database of
Systematic Reviews 2006 , Issue 1. Art. No.: CD002795. DOI:
10.1002/14651858.CD002795.pub2. At: http://onlinelibrary.
12. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety
of sertraline treatment of posttraumatic stress disorder: a
randomized controlled trial. JAMA 2000;283:1837–44 . At:
13. Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter,
double-blind comparison of sertraline and placebo in the
treatment of posttraumatic stress disorder. Arch Gen Psychiatry
2001;58:485–92. At: http://archpsyc.jamanetwork.com/article.
14. Stein DJ, Davidson J, Seedat S, et al. Paroxetine in the treatment
of post-traumatic stress disorder: pooled analysis of placebo-
controlled studies. Expert Opin Pharmacother 2003;4:1829–38 .
15. Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged
exposure therapy and paroxetine for PTSD related to the
World Trade Center attack: a randomized controlled trial. Am J
Psychiatry 2012;169:80–8 .
16. Spaulding AM. A pharmacotherapeutic approach to the
management of chronic posttraumatic stress disorder. J Pharm
17. Hammer MB, Deitsch SE, Brodrick PS, et al. Quetiapine
treatment in patients with posttraumatic stress disorder:
an open trial of adjunctive therapy. J Clin Psychopharmacol
18. Ahearn EP, Mussey M, Johnson C, et al. Quetiapine as an
adjunctive treatment for post-traumatic stress disorder:
an 8-week open-label study. Int Clin Psychopharmacol
19. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics
olanzapine and risperidone in the treatment of posttraumatic
stress disorder: a meta-analysis of randomized, double-blind,
placebo-controlled clinical trials. Int Clin Psychopharmacol
20. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo
controlled study of prazosin for trauma nightmares and sleep
disturbance in combat veterans with post-traumatic stress
disorder. Biol Psychiatry 2007;61:928–34.
21. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on
objective sleep measures and clinical symptoms in civilian
trauma posttraumatic stress disorder: a placebo-controlled
study. Biol Psychiatry 2008;63:629–32.
Submit your answers online before
1 November 2012 at www.psa.org.
au and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4
out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, fill in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
EVIDENCE IN PATIENT CARE
Links Archive Australian Pharmacist October 2012 Australian Pharmacist August 2012 Navigation Previous Page Next Page